转自：CGTN

#博鳌2025#【阿斯利康CEO：中国创新成果惠及全球患者】近日，阿斯利康加速布局中国研发版图，与北京经济技术开发区正式签约，投资25亿美元设立其全球第六个战略研发中心及高标准产业化项目。北京全球战略研发中心是继上海全球战略研发中心建立后，阿斯利康在中国建立的第二个全球战略研发中心。在博鳌亚洲论坛2025年年会期间，阿斯利康全球首席执行官苏博科在接受CGTN主持人@田薇_TianWei 专访时表示，中国正迎来制药创新的高峰期。北京汇聚顶尖学术资源、领先的生物科技和人工智能企业，已成为阿斯利康全球研发战略的关键一环。与此同时，上海团队也正引领全球临床研究，让中国医学创新服务于世界。AstraZeneca recently announced a $2.5 billion investment in Beijing to establish its sixth global strategic R&D center, along with major research and manufacturing agreements. This new center in Beijing will be AstraZeneca's second in China, following the opening of the first in Shanghai. In an exclusive interview with CGTN's Tian Wei at the Boao Forum for Asia Annual Conference 2025, AstraZeneca's CEO Pascal Soriot emphasized China's explosive growth in pharmaceutical innovation, positioning Beijing as the company's next major R&D hub. Meanwhile, the Shanghai team leads global clinical programs, bringing China's medical expertise to the world.